Maurizio Fava
Psychiatrist-in-Chief at Massachusetts General Hospital and Slater Family Professor of Psychiatry at Harvard Medical School
Data updated
Research Footprint
Maurizio Fava appears in 6 tracked papers (2016–2022), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression (526 citations).
Frequent co-authors: Sanjay Mathew, George Papakostas and Gerard Sanacora.
Background & Research
Maurizio Fava, MD, is a psychiatrist and depression researcher at Massachusetts General Hospital and Harvard Medical School. He founded the MGH Depression Clinical and Research Program and has led major clinical trial efforts in treatment-resistant depression, including work on rapidly acting antidepressant therapies such as ketamine. He previously trained in endocrinology and psychiatry at the University of Padova and Massachusetts General Hospital.
Key Impact
He is a leading depression researcher whose clinical trials helped establish ketamine and esketamine as rapid-acting treatments for treatment-resistant depression and suicidality.
Collaboration Network
24 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Maurizio Fava is associated with.